

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number  
**WO 2005/050214 A2**

(51) International Patent Classification<sup>7</sup>: **G01N 33/569**

(21) International Application Number:  
PCT/EP2004/011958

(22) International Filing Date: 22 October 2004 (22.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0326416.5 12 November 2003 (12.11.2003) GB  
60/519,152 12 November 2003 (12.11.2003) US

(71) Applicant (for all designated States except US): **HBV THERANOSTICA AB** [SE/SE]; c/o Karolinska Innovations AB, Fogdevreten 2B, S-172 77 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HELLSTROM, Ulla** [SE/SE]; Department of Communicable Disease Control and Prevention, Norrbacka, Karolinska Hospital, S-171 76 Stockholm (SE). **SYLVAN, Staffan** [SE/SE]; Department of Communicable Disease Control and Prevention, Smittskyddsläkarenheten, Landstinget i Uppsala Lan, S-751 85 Uppsala (SE).

(74) Agents: **SUTCLIFFE, Nicholas** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND MEANS RELATING TO HEPATITIS B INFECTION

(57) Abstract: The present inventors have discovered that the presence of antibodies reactive with residues 94-117 of the PreS1 component of the hepatitis B surface antigen (HBsAg) in an individual with HBV infection correlates closely with the effectiveness of interferon (IFN) in treating the individual. Methods and means based on this finding are provided herein.

WO 2005/050214 A2